AESGP Supports European Commission On Environment
Executive SummaryEuropean self-medication association AESGP is one of several European pharmaceutical industry bodies to have lent their backing to the latest European Commission strategic approach to pharmaceuticals in the environment.
You may also be interested in...
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.